“miragen-therapeutics” Archives

in
Entry Author Date Location
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal 12/12/19 Boulder/Denver
With Reverse Merger, Miragen to Go Public, Get $40M Boost From Investors 11/01/16 Boulder/Denver
MiRagen Lands $41M for MicroRNA Drugs in Cancer, Fibrosis 11/10/15 Boulder/Denver
MiRagen Therapeutics Garners $41,000,000 Series C Funding Round 11/10/15 Boulder/Denver
MiRagen Therapeutics Receives $8,499,962 New Financing Round 02/18/15 Boulder/Denver
MiRagen Therapeutics Lands $7,000,000 Series B Round 07/01/14 Boulder/Denver
MiRagen Therapeutics Raises $7M, Extends Deal with France’s Servier 06/26/14 Boulder/Denver
MiRagen Therapeutics Garners $20,000,000 Series B Funding Round 04/24/12 Boulder/Denver
MiRagen Therapeutics Obtains $6,000,000 New Funding Round 01/04/12 Boulder/Denver
Groove Biopharma Snags $6M to Push the Frontiers With MicroRNA Drugs 12/12/11 Seattle
Mirina Vs. Marina: The Looming Court Battle Over Biotech Company Names 08/16/10 Seattle
Accelerator’s MicroRNA Play, Mirina, Forges Ahead With One More Year of Cash 04/26/10 Seattle
Joule Debuts Biofuel Technology, Genzyme Cleans House, Avila Banks $30M, & More Boston-Area Life Sciences News 07/29/09 Boston
Archemix Signs MicroRNA Deal 07/23/09 Boston
Regulus, Leading Developer of MicroRNA Drugs, Prepares to Get Independence from Alnylam and Isis 01/21/09 San Diego
Takeda and Alnylam Join Forces, Carl Icahn Makes His Case, New England Biotech is Hot (Duh), & More Life Sciences News 05/29/08 Boston
Evergreen Rakes in the Green, NxStage Plans Two-Stage Deal, Atlas Places Big Bet on MicroRNA, & More Deals News 05/27/08 Boston
Page 1 of 1